A Study to Assess Safety, Tolerability and Immunogenicity of the Live Attenuated hRSV Vaccine rBCG-N-hRSV
NCT ID: NCT03213405
Last Updated: 2020-12-11
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
24 participants
INTERVENTIONAL
2017-06-27
2018-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
At Pontificia Universidad Católica de Chile, a vaccine has been developed to prevent hRSV infection, which is the conventional Bacillus Calmette Guerin (BCG) vaccine modified to recombinantly express the Nucleoprotein of hRSV (rBCG-N-hRSV). This vaccine has proven to be safe and immunogenic in different animal models, both in Chile and the USA. Doses of this vaccine have been manufactured under Current Good Manufacturing Practices (cGMP) conditions in USA, which are suitable to be tested in humans. Due to the unique immunogenic and safety characteristics observed in animal models used to test the efficacy of the rBCG-N-hRSV vaccine prototype, this clinical study will evaluate safety, tolerability and immunogenicity of the immunogenic cGMP formulation in healthy adults.
Main objective: To characterize the safety and tolerability of escalating doses of the rBCG-N-hRSV vaccine, including doses of 5x10\^3, 5x10\^4 and 1x10\^5 CFU (1%, 10% and 100% of the total dose) in healthy adult males of 18 to 50 years of age.
Secondary objectives:
1. To characterize the immune response against the Nucleoprotein of the hRSV in the previously stated escalating doses in the rBCG-N-hRSV.
2. To characterize the immune response against the Mycobacterium in the previously stated escalating doses in the rBCG-N-hRSV.
Study design: It corresponds to a phase I study, double blind (participant and personnel of the study) for the immunization of the tested vaccine or the control vaccine (Conventional BCG) within each cohort, to be performed in healthy adult males of 18 to 50 years of age.
After a full clinical and laboratory evaluation to discard diseases, immunodeficiencies and latent tuberculosis infection, the participants will be enrolled into three cohorts in a open and successive manner. Within each cohort, they will be randomly and in a blind-manner assigned to receive the tested vaccine (rBCG-N-hRSV) or the control vaccine (conventional BCG).
Cohort A: 6 participants vaccinated with 5x10\^3 CFU of the rBCG-N-hRSV (1/100 part of the full dose) and 2 participants vaccinated with the conventional BCG (full dose).
Cohort B: 6 participants vaccinated with 5x10\^4 CFU of the rBCG-N-hRSV (1/10 part of the full dose) and 2 participants vaccinated with the conventional BCG (full dose).
Cohort C: 6 participants vaccinated with 1x10\^5 CFU of the rBCG-N-hRSV (full dose) and 2 participants vaccinated with the conventional BCG (full dose).
Each cohort will be completed within two weeks, followed by a period of 4 weeks of follow-up, in which the security data will be evaluated by a Data and Safety Monitoring Board (DSMB), who will determinate whether, according to the previously defined parameters, the escalation to the next cohort is possible, the cohort must be repeated, or whether the study must be stopped.
The DSMB is constituted by 5 physician experts in microbiology, virology/vaccinology and tuberculosis, with a wide national recognition, affiliated to institutions different from the sponsoring institution.
Number of participants: A minimum of 24 subjects, 8 by cohort. 18 participants will receive the tested vaccine and 6 will receive the control vaccine.
Main variables: Safety and tolerability.
* Evaluation of reactogenicity (Local and systemic Adverse Events-AE)
* Evaluation of laboratory AE
* Serious AE
* Evaluation of the presence of the vaccine in body fluids
Secondary variables: Immunogenicity
* Evaluation of the immune response against M. bovis BCG.
* Evaluation of the immune response against hRSV-N.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Conventional BCG full dose
Participants will receive one full dose of the Conventional BCG vaccine administered as an intradermal injection at study entry.
Conventional BCG full dose
2x10\^5 colony forming units (CFU) of conventional BCG will be administered as an intradermal injection.
rBCG-N-hRSV 1/100 dose
Participants will receive one 1/100 dose of the rBCG-N-hRSV vaccine administered as an intradermal injection at study entry.
rBCG-N-hRSV 1/100
5x10\^3 colony forming units (CFU) of rBCG-N-hRSV will be administered as an intradermal injection.
rBCG-N-hRSV 1/10 dose
Participants will receive one 1/10 dose of the rBCG-N-hRSV vaccine administered as an intradermal injection at study entry.
rBCG-N-hRSV 1/10
5x10\^4 colony forming units (CFU) of rBCG-N-hRSV will be administered as an intradermal injection.
rBCG-N-hRSV full dose
Participants will receive one full dose of the rBCG-N-hRSV vaccine administered as an intradermal injection at study entry.
rBCG-N-hRSV full dose
1x10\^5 colony forming units (CFU) of rBCG-N-hRSV will be administered as an intradermal injection.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
rBCG-N-hRSV 1/100
5x10\^3 colony forming units (CFU) of rBCG-N-hRSV will be administered as an intradermal injection.
rBCG-N-hRSV 1/10
5x10\^4 colony forming units (CFU) of rBCG-N-hRSV will be administered as an intradermal injection.
rBCG-N-hRSV full dose
1x10\^5 colony forming units (CFU) of rBCG-N-hRSV will be administered as an intradermal injection.
Conventional BCG full dose
2x10\^5 colony forming units (CFU) of conventional BCG will be administered as an intradermal injection.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* To have accepted his voluntary participation through the sign of the informed consent.
* To be in good health, according to the medical history, physical examination and normal laboratory tests.
* To be vaccinated with BCG once or twice during his life.
All the volunteers must sign the Informed consent approved by the Ethic Committee of the "Facultad de Medicina" of the "Pontificia Universidad Católica de Chile", before starting the first screening visit.
Exclusion Criteria
* Body mass index lower than 19 and higher that 30 kg/m2 and/or weight under 50 kg.
* Not being able to attend all the study visits (face-to-face and call phones) or not follow the specified instructions (fasting, not doing intense physical exercise during the previous 24 hours to the visits and 72 hours post-vaccine).
* Signs of latent or active infectious diseases by Mycobacterium tuberculosis (TB): QuantiFERON-TB positive test or Chest X-ray suggesting Tuberculosis (TBC).
* Positive screening for Human Immunodeficiency Virus (HIV), Hepatitis B superficial antigen (HBsAG) and anti-Hepatitis C Virus (HCV).
* Evidence of primary or secondary immunodeficiency, determined by history, physical test and levels of serum immunoglobulins and lymphocytes sub-populations at the screening.
* Use of immunosuppressors during the last 6 months previous to the visit.
* Use of inhaled corticosteroids during the last year or with antecedents of bronchial hyper-reactivity.
* Antecedents of intradomiciliary contact with subjects with Tuberculosis or other mycobacteria, even when he/she is under treatment.
* Antecedents of substance abuse (drugs or alcohol), according to DSM IV (See footnote\*)
* Occurrence of any serious adverse event associated to the previous BCG vaccination.
* History of severe allergic reaction or anaphylaxis to vaccines
* History of severe infections (use of IV antibiotics, opportunist, latent TBC, herpes zoster) during six months previous to the visit.
* Not use or rejection to the use of contraceptives during the whole study (See footnote\*\*).
* Administration of Immunoglobulins or blood-derived products during the six months previous to the visit or the planning of its use during the study.
* Eczema at the vaccination site (deltoid zone).
* Antecedents of keloid scar.
* Being vaccinated with BCG during the last 10 years.
* History of being vaccinated with BCG three or more times or the presence of three BCG scars.
* Using other investigational products during the 30 days previous to the study.
* Administration of any vaccine during the 8 weeks previous to the recruitment.
* Planned administration of any other different vaccine 30 days after the vaccination with the rBCG-N-hRSV.
* Acute illness symptoms and/or feverish symptoms at the time or during the last seven days previous to the recruitment (fever defined as an oral or axillary temperature of \>38ºC).
(\*) Substance abuse (drugs or alcohol): Maladaptive pattern of substance abuse that leads to a deterioration or clinical significant discomfort, expressed by one or more associated problems, during a time of twelve months, in one of the four vitals areas: inability to achieve main obligations; consume in dangerous situations, such as driving a vehicle; legal problems; consume despite the social and interpersonal difficulties associated.
(\*\*) Given the remote possibility of negative effects produced by the vaccination in the sperm, the recruitment will be performed only to volunteers that are not planning of conceiving a child during the study duration. In each visit, the abstinence fulfillment will be checked or the use of effective contraceptive.
Eligibility criteria:
18 Years
50 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Comisión Nacional de Investigación Científica y Tecnológica
OTHER_GOV
Millennium Institute on Immunology and Immunotherapy
OTHER
Pontificia Universidad Catolica de Chile
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alexis M Kalergis, PhD
Role: STUDY_DIRECTOR
Pontificia Universidad Catolica de Chile
Katia Abarca, MD
Role: STUDY_DIRECTOR
Pontificia Universidad Catolica de Chile
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pontificia Universidad Católica de Chile
Santiago, , Chile
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Bueno SM, Gonzalez PA, Cautivo KM, Mora JE, Leiva ED, Tobar HE, Fennelly GJ, Eugenin EA, Jacobs WR Jr, Riedel CA, Kalergis AM. Protective T cell immunity against respiratory syncytial virus is efficiently induced by recombinant BCG. Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20822-7. doi: 10.1073/pnas.0806244105. Epub 2008 Dec 15.
Cautivo KM, Bueno SM, Cortes CM, Wozniak A, Riedel CA, Kalergis AM. Efficient lung recruitment of respiratory syncytial virus-specific Th1 cells induced by recombinant bacillus Calmette-Guerin promotes virus clearance and protects from infection. J Immunol. 2010 Dec 15;185(12):7633-45. doi: 10.4049/jimmunol.0903452. Epub 2010 Nov 17.
Cespedes PF, Bueno SM, Ramirez BA, Gomez RS, Riquelme SA, Palavecino CE, Mackern-Oberti JP, Mora JE, Depoil D, Sacristan C, Cammer M, Creneguy A, Nguyen TH, Riedel CA, Dustin ML, Kalergis AM. Surface expression of the hRSV nucleoprotein impairs immunological synapse formation with T cells. Proc Natl Acad Sci U S A. 2014 Aug 5;111(31):E3214-23. doi: 10.1073/pnas.1400760111. Epub 2014 Jul 23.
Palavecino CE, Cespedes PF, Gomez RS, Kalergis AM, Bueno SM. Immunization with a recombinant bacillus Calmette-Guerin strain confers protective Th1 immunity against the human metapneumovirus. J Immunol. 2014 Jan 1;192(1):214-23. doi: 10.4049/jimmunol.1300118. Epub 2013 Dec 6.
Cespedes PF, Rey-Jurado E, Espinoza JA, Rivera CA, Canedo-Marroquin G, Bueno SM, Kalergis AM. A single, low dose of a cGMP recombinant BCG vaccine elicits protective T cell immunity against the human respiratory syncytial virus infection and prevents lung pathology in mice. Vaccine. 2017 Feb 1;35(5):757-766. doi: 10.1016/j.vaccine.2016.12.048. Epub 2017 Jan 5.
Pacheco GA, Andrade CA, Galvez NMS, Vazquez Y, Rodriguez-Guilarte L, Abarca K, Gonzalez PA, Bueno SM, Kalergis AM. Characterization of the humoral and cellular immunity induced by a recombinant BCG vaccine for the respiratory syncytial virus in healthy adults. Front Immunol. 2023 Jul 18;14:1215893. doi: 10.3389/fimmu.2023.1215893. eCollection 2023.
Abarca K, Rey-Jurado E, Munoz-Durango N, Vazquez Y, Soto JA, Galvez NMS, Valdes-Ferrada J, Iturriaga C, Urzua M, Borzutzky A, Cerda J, Villarroel L, Madrid V, Gonzalez PA, Gonzalez-Aramundiz JV, Bueno SM, Kalergis AM. Safety and immunogenicity evaluation of recombinant BCG vaccine against respiratory syncytial virus in a randomized, double-blind, placebo-controlled phase I clinical trial. EClinicalMedicine. 2020 Oct 6;27:100517. doi: 10.1016/j.eclinm.2020.100517. eCollection 2020 Oct.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Document Type: Informed Consent Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
rBCG-N-VRSh 001
Identifier Type: OTHER
Identifier Source: secondary_id
15-216
Identifier Type: -
Identifier Source: org_study_id